Prothena (PRTA) Competitors $6.47 +0.15 (+2.37%) Closing price 07/3/2025 03:46 PM EasternExtended Trading$6.41 -0.06 (-0.94%) As of 07/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTA vs. GPCR, CVAC, CALT, AUPH, BGM, NAGE, AMPH, DYN, ABCL, and PAHCShould you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Aurinia Pharmaceuticals (AUPH), BGM Group (BGM), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Prothena vs. Its Competitors Structure Therapeutics CureVac Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals BGM Group Niagen Bioscience Amphastar Pharmaceuticals Dyne Therapeutics AbCellera Biologics Phibro Animal Health Prothena (NASDAQ:PRTA) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk. Do insiders & institutionals believe in PRTA or GPCR? 97.1% of Prothena shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 9.2% of Prothena shares are owned by company insiders. Comparatively, 9.4% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor PRTA or GPCR? In the previous week, Prothena had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 2 mentions for Prothena and 1 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.02 beat Prothena's score of 0.34 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer PRTA or GPCR? Prothena presently has a consensus price target of $31.50, indicating a potential upside of 386.86%. Structure Therapeutics has a consensus price target of $76.17, indicating a potential upside of 269.40%. Given Prothena's higher possible upside, equities research analysts clearly believe Prothena is more favorable than Structure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, PRTA or GPCR? Prothena has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProthena$137.94M2.52-$122.31M-$2.08-3.11Structure TherapeuticsN/AN/A-$122.53M-$0.87-23.70 Which has more volatility & risk, PRTA or GPCR? Prothena has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.87, suggesting that its share price is 287% less volatile than the S&P 500. Is PRTA or GPCR more profitable? Structure Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -79.94%. Structure Therapeutics' return on equity of -16.35% beat Prothena's return on equity.Company Net Margins Return on Equity Return on Assets Prothena-79.94% -21.61% -19.32% Structure Therapeutics N/A -16.35%-15.71% SummaryStructure Therapeutics beats Prothena on 8 of the 15 factors compared between the two stocks. Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTA vs. The Competition Export to ExcelMetricProthenaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$348.26M$2.88B$5.50B$9.01BDividend YieldN/A2.43%5.38%4.04%P/E Ratio-3.1121.5627.6020.30Price / Sales2.52172.94369.09103.84Price / CashN/A41.9536.6357.47Price / Book0.717.518.055.68Net Income-$122.31M-$55.05M$3.18B$249.13M7 Day Performance6.41%4.61%2.82%3.30%1 Month Performance32.58%4.89%3.70%5.20%1 Year Performance-67.76%5.84%35.41%21.38% Prothena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTAProthena3.1751 of 5 stars$6.47+2.4%$31.50+386.9%-67.8%$348.26M$137.94M-3.11130GPCRStructure Therapeutics2.9478 of 5 stars$20.74-1.6%$76.17+267.2%-44.9%$1.21BN/A-23.84136CVACCureVac4.6485 of 5 stars$5.43+0.9%$6.83+25.8%+72.9%$1.21B$579.18M5.90880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals3.2625 of 5 stars$8.47-2.0%$11.50+35.8%+38.3%$1.17B$235.13M30.25300BGMBGM GroupN/A$10.59-11.5%N/AN/A$1.16B$25.10M0.00298NAGENiagen Bioscience1.5267 of 5 stars$14.41+1.3%$19.50+35.3%N/A$1.12B$99.60M84.76120AMPHAmphastar Pharmaceuticals4.3798 of 5 stars$22.96-0.5%$32.33+40.8%-39.9%$1.09B$731.97M8.322,028News CoverageDYNDyne Therapeutics3.5176 of 5 stars$9.52-0.5%$41.13+332.0%-73.5%$1.09BN/A-2.65100ABCLAbCellera Biologics2.503 of 5 stars$3.43-5.0%$8.33+143.0%+40.4%$1.08B$28.83M-6.12500High Trading VolumePAHCPhibro Animal Health3.6535 of 5 stars$25.54-0.5%$21.80-14.6%+63.3%$1.04B$1.02B32.741,940 Related Companies and Tools Related Companies Structure Therapeutics Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Aurinia Pharmaceuticals Competitors BGM Group Competitors Niagen Bioscience Competitors Amphastar Pharmaceuticals Competitors Dyne Therapeutics Competitors AbCellera Biologics Competitors Phibro Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTA) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
